|
INTRODUCTION
Osteoarthritis is a highly prevalent disease, affecting approximately 12% of the population in the seven major pharmaceutical markets. As
osteoarthritis is associated with aging, the impact of this disease will continue to grow over the next decade. With no cure, physicians and patients
alike attempt to control the pain, stiffness, and other adverse effects. This analysis examines current treatment trends in the fight against this
disease.
SCOPE OF THE REPORT
- Covers the seven major pharmaceutical markets, US, Japan, France, Germany, Italy, Spain, and the UK
- The primary drug classes covered include analgesics, traditional NSAIDs, COX-II inhibitors, and oral and injectable steroids
- Treatment trends vary significantly from country to country, making this cross-market analysis invaluable in understanding the OA market
REPORT HIGHLIGHTS
As osteoarthritis presently has no cure, and physicians have little hope that a cure will be available shortly, treatment strategies focus on
treating the disease symptoms with minimal side effects. Interestingly, physicians show a greater interest in more effective, safer drugs than a
"super-drug" that would cure OA.
In several markets, a significant proportion of diagnosed mild and moderate OA patients are treated solely with non-pharmacologic strategies.
Products with a strong safety profile and low cost require only a moderate efficacy level to gain sales to patients that might otherwise take a
non-pharmacological approach.
KEY REASONS TO BUY THIS REPORT
- Understand treatment trends across seven markets, by disease severity, to evaluate potential for current and pipeline products
- Assess the potential for COX-II inhibitors in Japan, based on the success of minimally selective NSAIDs such as Mobic (meloxicam)
- Evaluate markets where the patient population, or the use of a drug class in particular, is underpenetrated, to best position your products
- Identify the leading products in each market, to build an understanding of the factors that contribute to success on the OA market in each
country
| 
View Cart
